Skip to main content
SpringerLink
Log in

Chemotherapy for Diffuse Low-Grade Gliomas

  • Chapter
  • First Online:
Diffuse Low-Grade Gliomas in Adults

  • 1278 Accesses

Abstract

Diffuse low-grade gliomas are rare tumors. Therapeutic strategies have dramatically changed in recent years, thanks to observational data, insight of some authors, retrospective studies, and, incidentally, results of few phase III and II trials. Surgery has become the cornerstone of the treatment. Radiotherapy, because of its potential delayed neurotoxicity and the equivalent results in terms of survival whatever the timing of the treatment (early or late), is increasingly offered to patients with unresectable tumors (or tumor that cannot be reoperated) and in case of progression after chemotherapy. Chemotherapy, subject of this chapter, has shown clinical benefits regarding tumor progression for nonsurgical patients, before or after radiotherapy: initial chemosensitivity almost constant, improvement of epilepsy and thus of cognition, and preservation of quality of life (despite a possible transient alteration). Its articulation with surgery has been more recently discussed by allowing, thanks to tumor shrinkage, subtotal or total resection (whose impact on anaplastic transformation and survival has been demonstrated), in addition to potential effects on cerebral plasticity. It remains to show the direct or indirect impact on survival, to refine its risk-benefit ratio, especially in the context of prolonged treatment with temozolomide, and to develop further research from a neurological (impact on plasticity) and oncological (involved molecular pathways, identifying new therapeutic targets) points of view.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Whittle IR. The dilemma of low grade glioma. J Neurol Neurosurg Psychiatry. 2004;75 Suppl 2:ii31–6.

    Article  PubMed  CAS  Google Scholar 

  2. Duffau H. The challenge to remove diffuse low-grade gliomas while preserving brain functions. Acta Neurochir (Wien). 2012;154:569–74.

    Article  Google Scholar 

  3. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115:948–65.

    Article  PubMed  Google Scholar 

  4. Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH, Beute GN, Sluimer JD, Slotman BJ, Reijneveld JC, Heimans JJ. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–8.

    Article  PubMed  Google Scholar 

  5. Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, Quagliana JM, Al-Sarraf M. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a southwest Oncology Group Study. J Neurosurg. 1993;78:909–14.

    Article  PubMed  CAS  Google Scholar 

  6. Cairncross JG, Macdonald DR. Oligodendroglioma: a new chemosensitive tumor. J Clin Oncol. 1990;8:2090–1.

    PubMed  CAS  Google Scholar 

  7. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol. 1990;27:573–4.

    Article  PubMed  CAS  Google Scholar 

  8. Mason WP, Krol GS, DeAngelis LM. Low grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46:203–7.

    Article  PubMed  CAS  Google Scholar 

  9. Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43:1066–73.

    Article  PubMed  CAS  Google Scholar 

  10. Ducray F. Chemotherapy for diffuse low-grade gliomas in adults. Rev Neurol (Paris). 2011;167:673–9.

    Article  CAS  Google Scholar 

  11. Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010;10:224–31.

    Article  PubMed  CAS  Google Scholar 

  12. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W, European Federation of Neurological Societies. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17:1124–33.

    Article  PubMed  CAS  Google Scholar 

  13. Gutin PH, Wilson CB, Kumar AR, Boldrey EB, Levin V, Powell M, Enot KJ. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer. 1975;35:1398–404.

    Article  PubMed  CAS  Google Scholar 

  14. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980;64:237–44.

    PubMed  CAS  Google Scholar 

  15. Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg. 1985;63:218–23.

    Article  PubMed  CAS  Google Scholar 

  16. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008;89:187–93.

    Article  PubMed  CAS  Google Scholar 

  17. Lashkari HP, Saso S, Moreno L, Athanasiou T, Zacharoulis S. Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. J Neurooncol. 2011;105:135–47.

    Article  PubMed  CAS  Google Scholar 

  18. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.

    PubMed  CAS  Google Scholar 

  19. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C. Phase II study of primary temozolomide chemotherapy in patients with WHO II grade gliomas. Ann Oncol. 2003;14:1715–21.

    Article  PubMed  CAS  Google Scholar 

  20. Buckner JC, Gesme Jr D, O’Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R. Phase II trial of procarbazine, lomustine and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251–5.

    Article  PubMed  CAS  Google Scholar 

  21. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM. Temozolomide chemotherapy for progressive low-grade glioma :clinical benefits and radiological response. Ann Oncol. 2003;14:1722–6.

    Article  PubMed  CAS  Google Scholar 

  22. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.

    Article  PubMed  Google Scholar 

  23. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Crinière E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broët P, Sanson M, Delattre JY. Temozolomide as initial treatment for adults with low-grade ­oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22(15):3133–8.

    Article  PubMed  CAS  Google Scholar 

  24. Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61:484–90.

    Article  PubMed  CAS  Google Scholar 

  25. Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, Cornu P, Van Effenterre R, Alvord Jr EC, Capelle L. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524–8.

    Article  PubMed  Google Scholar 

  26. Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, Campello C, Gozé C, Rigau V, Moritz-Gasser S, Kerr C, Rudà R, Soffietti R, Bauchet L, Duffau H. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol. 2012;106:353–66.

    Article  PubMed  CAS  Google Scholar 

  27. Duffau H, Capelle L, Lopes M, Bitar A, Sichez JP, van Effenterre R. Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionectomy. Acta Neurochir (Wien). 2002;144:563–72.

    Article  CAS  Google Scholar 

  28. Stockhammer F, Misch M, Helms HJ, Lengler U, Prall F, von Deimling A, Hartmann C. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012;21:194–7.

    Article  PubMed  Google Scholar 

  29. Kurzwelly D, Herrlinger U, Simon M. Seizures in patients with low-grade gliomas – incidence, pathogenesis, surgical management, and pharmacotherapy. Adv Tech Stand Neurosurg. 2010;35:81–111.

    Article  PubMed  CAS  Google Scholar 

  30. Hu A, Xu Z, Kim RY, Nguyen A, Lee JW, Kesari S. Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients. Epilepsy Res. 2011;95:270–2.

    Article  PubMed  Google Scholar 

  31. Ochsenbein AF, Schubert AD, Vassella E, Mariani L. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Neurooncol. 2011;103:343–51.

    Article  PubMed  CAS  Google Scholar 

  32. Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME, Schiff D. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg. 2011;114:1617–21.

    Article  PubMed  Google Scholar 

  33. Taillandier L, Duffau H. Epilepsy and insular grade II gliomas: an interdisciplinary point of view from a ­retrospective monocentric series of 46 cases. Neurosurg Focus. 2009;27(2):E8.

    Article  PubMed  Google Scholar 

  34. Maschio M, Dinapoli L, Mingoia M, Sperati F, Pace A, Pompili A, Carapella CM, Vidiri A, Muti P. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol. 2011;258:2100–4.

    Article  PubMed  CAS  Google Scholar 

  35. Vecht CJ, Wilms EB. Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther. 2010;10:663–9.

    Article  PubMed  Google Scholar 

  36. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77:1156–64.

    Article  PubMed  CAS  Google Scholar 

  37. Moritz-Gasser S, Herbet G, Maldonado IL, Duffau H. Lexical access speed is significantly correlated with the return to professional activities after awake surgery for low-grade gliomas. J Neurooncol. 2012;107:633–41.

    Article  PubMed  Google Scholar 

  38. Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol. 2011;29:4430–5.

    Article  PubMed  Google Scholar 

  39. Correa DD, DeAngelis LM, Shi W, Thaler HT, Lin M, Abrey LE. Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol. 2007;81:175–84.

    Article  PubMed  Google Scholar 

  40. Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol. 2008;86:321–7.

    Article  PubMed  Google Scholar 

  41. Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, Allgeier A, Bottomley A, European Organisation for Research and Treatment of Cancer. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007;25:5723–30.

    Article  PubMed  Google Scholar 

  42. Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009;11:59–68.

    Article  PubMed  CAS  Google Scholar 

  43. Chang EF, Clark A, Smith JS, Polley MY, Chang SM, Barbaro NM, Parsa AT, McDermott MW, Berger MS. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. J Neurosurg. 2011;114:566–73.

    Article  PubMed  Google Scholar 

  44. Prabhu VC, Khaldi A, Barton KP, Melian E, Schneck MJ, Primeau MJ, Lee JM. Management of diffuse low-grade cerebral gliomas. Neurol Clin. 2010;28:1037–59.

    Article  PubMed  Google Scholar 

  45. Greene MH, Boice Jr JD, Greer BE, Blessing JA, Dembo AJ. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med. 1982;307:1416–21.

    Article  PubMed  CAS  Google Scholar 

  46. Boice Jr JD, Greene MH, Killen Jr JY, Ellenberg SS, Keehn RJ, McFadden E, Chen TT, Fraumeni Jr JF. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med. 1983;309:1079–84.

    Article  PubMed  Google Scholar 

  47. Greene MH, Boice Jr JD, Strike TA. Carmustine as a cause of acute nonlymphocytic leukemia. N Engl J Med. 1985;313:579.

    Article  PubMed  CAS  Google Scholar 

  48. Baehring JM, Marks PW. Treatment-related myelodysplasia in patients with primary brain tumors. Neuro Oncol. 2012;14:529–40.

    Article  PubMed  CAS  Google Scholar 

  49. Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with pro- longed postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol. 1998;44(3):313–6.

    Article  PubMed  CAS  Google Scholar 

  50. Perry JR, Brown MT, Gockerman JP. Acute leukemia following treatment of malignant glioma. J Neurooncol. 1998;40:39–46.

    Article  PubMed  CAS  Google Scholar 

  51. Khasraw M, Bell D, Wheeler H. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci. 2009;16:854–5.

    Article  PubMed  CAS  Google Scholar 

  52. Natelson EA, Pyatt D. Temozolomide-induced myelodysplasia. Adv Hematol Vol. 2010;Article ID 760402:5.

    Google Scholar 

  53. Harel S, Fermé C, Poirot C. Management of fertility in patients treated for Hodgkin’s lymphoma. Haematologica. 2011;96:1692–9.

    Article  PubMed  CAS  Google Scholar 

  54. Dobrzyńska MM, Czajka U, Słowikowska MG. Reproductive effects after exposure of male mice to vincristine and to a combination of X-rays and vincristine. Reprod Fertil Dev. 2005;17:759–67.

    Article  PubMed  Google Scholar 

  55. Sitbon Sitruk L, Sanson M, Prades M, Lefebvre G, Schubert B, Poirot C. Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide. Gynecol Obstet Fertil. 2010;38:660–2.

    Article  PubMed  CAS  Google Scholar 

  56. Palmieri C, Brock C, Newlands ES. Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma. J Neurooncol. 2005;73:185.

    Article  PubMed  Google Scholar 

  57. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63:761–7.

    Article  PubMed  CAS  Google Scholar 

  58. Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, Sklar C, Robison LL, Childhood Cancer Survivor Study. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer. 2002;95:2431–41.

    Article  PubMed  Google Scholar 

  59. Sarganas G, Orzechowski HD, Klimpel A, Thomae M, Kauffmann W, Herbst H, Bronder E, Garbe E. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol. 2012;14:541–6.

    Article  PubMed  CAS  Google Scholar 

  60. Mandonnet E, Duffau H, Bauchet L. A new tool for grade II glioma studies: plotting cumulative time with quality of life versus time to malignant transformation. J Neurooncol. 2012;106:213–5.

    Article  PubMed  Google Scholar 

  61. Klein M. Health-related quality of life aspects in patients with low-grade glioma. Adv Tech Stand Neurosurg. 2010;35:213–35.

    Article  PubMed  CAS  Google Scholar 

  62. Erickson BJ, Wood CP, Kaufmann TJ, Patriarche JW, Mandrekar J. Optimal presentation modes for detecting brain tumor progression. AJNR Am J Neuroradiol. 2011;32:1652–57.

    Article  PubMed  CAS  Google Scholar 

  63. Mandonnet E, Pallud J, Clatz O, Taillandier L, Konukoglu E, Duffau H, Capelle L. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev. 2008;31:263–9.

    Article  PubMed  Google Scholar 

  64. Nelson SJ. Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed. 2011;24:734–49.

    PubMed  Google Scholar 

  65. Guillevin R, Menuel C, Taillibert S, Capelle L, Costalat R, Abud L, Habas C, De Marco G, Hoang-Xuan K, Chiras J, Vallée JN. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. Br J Cancer. 2011;104:1854–61.

    Article  PubMed  CAS  Google Scholar 

  66. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB, European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.

    Article  PubMed  Google Scholar 

  67. Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, Mukhopadhyay D, Kim W, Liau LM, Chang SM, Smith JS, Berger MS, McDermott MW. Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg. 2009;111:203–10.

    Article  PubMed  Google Scholar 

  68. Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D, Shaw EG. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 2011;81:218–24.

    Article  PubMed  Google Scholar 

  69. Vöglein J, Tüttenberg J, Weimer M, Gerigk L, Kauczor HU, Essig M, Weber MA. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure. Invest Radiol. 2011;46:390–400.

    Article  PubMed  Google Scholar 

  70. Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, Leach MO, Dzik-Jurasz AS. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer. 2004;90:781–6.

    Article  PubMed  CAS  Google Scholar 

  71. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177:2708–14.

    Article  PubMed  Google Scholar 

  72. Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Rev Neurol (Paris). 2011;167:683–90.

    Article  CAS  Google Scholar 

  73. Pollo B. Neuropathological diagnosis of brain tumours. Neurol Sci. 2011;32 Suppl 2:S209–11.

    Article  PubMed  Google Scholar 

  74. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M, for the German Glioma Network. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17:4588–99.

    Article  PubMed  CAS  Google Scholar 

  75. Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. J Neurooncol. 2011;102:443–9.

    Article  PubMed  Google Scholar 

  76. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K. Temozolomide for low grade gliomas: predictive impact of 1p/19q on response and outcome. Neurology. 2007;68:1831–6.

    Article  PubMed  CAS  Google Scholar 

  77. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75:1560–6.

    Article  PubMed  CAS  Google Scholar 

  78. Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent MJ, Dutch Society for Neuro-Oncology. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol. 2011;13:235–41.

    Article  PubMed  CAS  Google Scholar 

  79. Musat E, Roelofs E, Bar-Deroma R, Fenton P, Gulyban A, Collette L, Stupp R, Weber DC, Bernard Davis J, Aird E, Baumert BG. Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033–26033: First evaluation of quality of radiotherapy planning. Radiother Oncol. 2010;95:218–24.

    Article  PubMed  Google Scholar 

  80. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon 2nd JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646–51.

    Article  PubMed  CAS  Google Scholar 

  81. van den Bent MJ. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin Oncol. 2003;30(6 Suppl 19):39–44.

    Article  PubMed  Google Scholar 

  82. Shaw EG, Wang M, Coons S, Brachman D, Buckner JC, Stelzer K, Barger G, Brown PD, Gilbert MR, Mehta MP. Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT  +  procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). 2008 ASCO annual meeting. J Clin Oncol 2008; 26(May 20 suppl):abstr 2006

    Google Scholar 

  83. Baumert BG, Stupp R. Is there a place for radiotherapy in low-grade gliomas? Adv Tech Stand Neurosurg. 2010;35:159–82.

    Article  PubMed  CAS  Google Scholar 

  84. Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009;10:231–42.

    Article  PubMed  Google Scholar 

  85. Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY, ANOCEF Group. Initial chemotherapy in gliomatosis cerebri. Neurology. 2004;63:270–5.

    Article  PubMed  CAS  Google Scholar 

  86. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009;11:69–79.

    Article  PubMed  CAS  Google Scholar 

  87. Duffau H, Taillandier L, Capelle L. Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma. J Neurooncol. 2006;80:171–6.

    Article  PubMed  Google Scholar 

  88. Spena G, Garbossa D, Barletta L, Prevost C, Versari P. Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection – case report. Neurol Med Chir (Tokyo). 2010;50:410–3.

    Article  Google Scholar 

  89. Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien). 2009;151:427–36.

    Article  Google Scholar 

  90. Imani F, Boada FE, Lieberman FS, Davis DK, Deeb EL, Mountz JM. Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression. J Neuroimaging. 2012;22:184–90.

    Article  PubMed  Google Scholar 

  91. Freyschlag CF, Smolczyk DR, Janzen E, Schmieder K, Thomé C, Lohr F, Wenz F, Weiss C, Tuettenberg J, Seiz M. Prolonged administration of temozolomide in adult patients with anaplastic glioma. Anticancer Res. 2011;31:3873–7.

    PubMed  CAS  Google Scholar 

  92. Chamberlain MC. Temozolomide: therapeutic limitations in the treatment of adult ­high-grade gliomas. Expert Rev Neurother. 2010;10:1537–44.

    Article  PubMed  CAS  Google Scholar 

  93. Peyre M, Cartalat-Carel S, Meyronet D, Ricard D, Jouvet A, Pallud J, Mokhtari K, Guyotat J, Jouanneau E, Sunyach MP, Frappaz D, Honnorat J, Ducray F. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12:1078–82.

    Article  PubMed  Google Scholar 

  94. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer. 2005;104:2473–6.

    Article  PubMed  CAS  Google Scholar 

  95. Kaloshi G, SierradelRio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. J Neurooncol. 2010;100:439–41.

    Article  PubMed  CAS  Google Scholar 

  96. Lesser GJ. Chemotherapy of low-grade gliomas. Semin Radiat Oncol. 2001;11:138–44.

    Article  PubMed  CAS  Google Scholar 

  97. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J Neurooncol. 2002;59:157–63.

    Article  PubMed  Google Scholar 

  98. Ius T, Angelini E, Thiebaut de Schotten M, Mandonnet E, Duffau H. Evidence for potentials and limitations of brain plasticity using an atlas of functional resectability of WHO grade II gliomas: towards a “minimal common brain”. Neuroimage. 2011;56:992–1000.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurooncology Unit, Department of Neurology, University Hospital, Hospital Central, 29 Avenue du Marechal de Lattre de Tassigny, 54035, Nancy, France

    Luc Taillandier MD, PhD

Authors
  1. Luc Taillandier MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luc Taillandier MD, PhD .

Editor information

Editors and Affiliations

  1. , INSERM U1051, Institute for Neurosciences of Montpelli, av. Augustin Fliche 80, Montpellier, 34295, France

    Hugues Duffau

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Taillandier, L. (2013). Chemotherapy for Diffuse Low-Grade Gliomas. In: Duffau, H. (eds) Diffuse Low-Grade Gliomas in Adults. Springer, London. https://doi.org/10.1007/978-1-4471-2213-5_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2213-5_25

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2212-8

  • Online ISBN: 978-1-4471-2213-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation